

INDIA PHARMA 2021

6th International Conference on Pharmaceutical Industry

25th- 26th Feb 2021 and 1-2nd Mar 2021

Theme: "Indian Pharma Industry- Future is Now"

Conference Program

DATE / TIME	EVENT
DAY 1, 25th Feb 2021	
1000-1100	Inaugural Session
1100-1130	India Pharma and India Medical Devices Awards 2021
1130-1200	BREAK
1200-1400	INDIA PHARMA CEO Roundtable with Hon'ble Union Minister for Chemicals & Fertilizers, Government of India (By Invitation only)
1400-1430	LUNCH BREAK
1700-1900	JOINT SESSION: International Drug Regulatory Session with Pharmaceutical & Medical Device Industry
DAY 2, 26th February 2021	
1000-2000	Global Investors Meet by Invest India
DAY 3, 1st March 2021	
1000-1130	SESSION 1: Manufacturing and Supply Chain: <i>Strengthening base in domestic and global markets</i>
	<p>Session Brief:</p> <ul style="list-style-type: none"> • How to develop capabilities in APIs and enable manufacture of complex generics, bio-similars, gene & cell therapies etc. • Ease of doing business is the most important enabler to set up world class manufacturing facilities • How to enhance attractiveness of manufacturing sector to attract the best talent in India and abroad • Given the growth ambitions, how to encourage and setup of Pharmaceutical machine manufacturing facilities in India that would result in lower fixed costs, savings in forex and reduction in time to set up additional facilities.
1130-1145	BREAK
1145-1315	SESSION 2: Ecosystem for R&D and Innovation: <i>Moving up the Value Chain</i>
	<p>Session Brief:</p> <p>For the last few years pharma, biotech innovation and start-ups have gained significant momentum in India. Pharma & Bio-tech sectors are amongst main contributory sectors to the ambitious goal of 5 Trillion USD aspired to make India a Start-up nation witnessing rapid growth in numbers of innovations and Start-ups in the country. Though the industry is responsible for some of the greatest medical advancements, there are still many health challenges needs to be addressed in areas like non-communicable diseases, infectious diseases and neglected diseases. Policymakers have an important role to play in ensuring that an enabling environment is maintained to support sustainable innovation. Hence, this session is aims to provide a platform to:</p>

	<ul style="list-style-type: none"> • Deliberate how to foster an ecosystem for innovation. • Identify trends affecting innovation in the research-based industry. • Deliberate how can we improve access to quality infrastructure for sustainable clinical trials, strengthening R&D centres and biotech clusters, and improving availability of data. • Identify ways to increase the variety of R&D financing resources to encourage pharmaceutical R&D, such as providing subsidies and tax incentives for start-ups focused on R&D.
1315-1400	LUNCH BREAK
1400-1530	SESSION 3: Healthcare Delivery and Market Access: <i>Achieving sustainable and equitable access</i>
	<p>Key Discussion Points:</p> <ul style="list-style-type: none"> • This session explores the key opportunities that need to be realized to improve the market access of the drugs in the country. • Innovative Pricing models • Digitization, tele-consult • Adult Immunization
1530-1545	BREAK
1545-1715	SESSION 4: Next Frontiers
	<p>Key Discussion Points:</p> <ul style="list-style-type: none"> • Overarching regulatory body • Preventives (OTC, wellness) • Rare Diseases Policy • Need for “Evidence Based Procurement Decisions (HE Concepts)” with a focus on mid- long term perspective for the Healthcare systems resource utilization. • Pharmacoeconomics and how they are driving efficiencies and better health outcomes • Digital/ Optimized systems – how they can be an effective tool to decrease price to patients coupled with offering value-added services for improving patient access to medicines. • New drug delivery models – E-pharmacy